ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Diabetes and endocrinology · Diabetologia · 2026-07-17

In 24 adults with type 2 diabetes randomised to dapagliflozin (n=17) or placebo (n=7) for 6 months, LDL-ApoB100 fractional catabolism was unchanged (0.88 vs 0.79 pool/day, p=0.16); VLDL1 catabolism shifted from direct to indirect pathways.

RCTn = 24
Vergès et al. Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL1/VLDL2 catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.